AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- The combination of gefitinib and trastuzumab shows promise for the treatment of metastatic breast cancer (MBC).
"Despite new therapies and several treatment options," MBC "remains incurable," oncologists in Germany explained. "One reason for the low median survival rate may be intense cross-talk between growth factor receptors such as the epidermal growth factor receptor (EGFR/HER1) and the HER2 growth factor receptor."
A. Schneeweiss and colleagues at the University of Heidelberg described "the case history of a patient with MBC whose disease had progressed despite surgery, radiotherapy and four different chemotherapy regimens, including trastuzumab (a monoclonal antibody that specifically blocks HER2) combined with docetaxel.
"However, treatment with 500 mg/day gefitinib ('Iressa', ZD1839), an EGFR tyrosine kinase inhibitor, and trastuzumab (2 mg/kg/week) caused a rapid and sustained regression of breast cancer metastases in skin and lymph nodes," according to the report.
"Thus, for patients with MBC whose tumors ...